BEAM · Insider Trading
Beam Therapeutics Inc. Common Stock
Every open-market purchase and sale reported by BEAM officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-10-16 | John M. Evans | CEO | MIXED | — | −$1.14M |
| 2026-10-02 | Bethany J Cavanagh | SVP, Finance and Treasurer | Sell | −187 | −$4.56K |
| 2026-09-25 | Giuseppe Ciaramella | President | G | −123,407 | — |
| 2026-07-29 | Amy Simon | Chief Medical Officer | Sell | −16,667 | −$429.04K |
| 2026-07-02 | Amy Simon | Chief Medical Officer | Sell | −373 | −$12.95K |
| 2026-07-01 | John M. Evans | CEO | MIXED | — | −$1.70M |
| 2026-06-29 | FMR LLC | 10%+ Owner | Sell | −284,860 | −$10.04M |
| 2026-06-22 | Giuseppe Ciaramella | President | M | +35,505 | +$34.23K |
| 2026-06-05 | Graham K Cooper | Director | A | +19,676 deriv. | — |
| 2026-06-05 | John Maraganore | Director | A | +19,676 deriv. | — |
| 2026-06-05 | Christi Shaw | Director | A | +19,676 deriv. | — |
| 2026-06-05 | Mark Fishman | Director | A | +19,676 deriv. | — |
| 2026-06-05 | Kathleen E Walsh | Director | A | +19,676 deriv. | — |
| 2026-06-05 | Chirfi Guindo | Director | A | +19,676 deriv. | — |
| 2026-04-06 | Christine Bellon | Chief Legal Officer | Sell | −5,956 | −$146.40K |
| 2026-04-06 | Amy Simon | Chief Medical Officer | Sell | −6,700 | −$164.69K |
| 2026-04-06 | John M. Evans | CEO | Sell | −30,078 | −$739.32K |
| 2026-04-06 | Bethany J Cavanagh | SVP, Finance and Treasurer | Sell | −3,242 | −$79.69K |
| 2026-04-06 | Giuseppe Ciaramella | President | Sell | −11,810 | −$290.29K |
| 2026-04-02 | Bethany J Cavanagh | SVP, Finance and Treasurer | A | +20,000 | — |
| 2026-04-02 | Christine Bellon | Chief Legal Officer | A | +20,000 | — |
| 2026-04-02 | Sravan Kumar Emany | Chief Financial Officer | A | +31,750 | — |
| 2026-04-02 | Giuseppe Ciaramella | President | A | +40,000 | — |
| 2026-04-02 | Amy Simon | Chief Medical Officer | A | +31,750 | — |
| 2026-04-01 | John M. Evans | CEO | MIXED | +90,000 | −$1.09M |
| 2026-02-26 | Giuseppe Ciaramella | President | MIXED | — | −$525.04K |
| 2026-02-02 | Sravan Kumar Emany | Chief Financial Officer | A | +63,500 deriv. | — |
| 2026-02-02 | Bethany J Cavanagh | SVP, Finance and Treasurer | A | +40,000 deriv. | — |
| 2026-02-02 | Christine Bellon | Chief Legal Officer | A | +40,000 deriv. | — |
| 2026-02-02 | Giuseppe Ciaramella | President | A | +80,000 deriv. | — |
| 2026-02-02 | John M. Evans | CEO | MIXED | — | −$1.41M |
| 2026-02-02 | Amy Simon | Chief Medical Officer | A | +88,500 deriv. | — |
| 2026-01-26 | Christine Bellon | Chief Legal Officer | Sell | −1,371 | −$46.61K |
| 2026-01-26 | Bethany J Cavanagh | SVP, Finance and Treasurer | Sell | −6,198 | −$216.93K |
| 2026-01-21 | Bethany J Cavanagh | SVP, Finance and Treasurer | Sell | −3,034 | −$91.38K |
| 2026-01-20 | Christine Bellon | Chief Legal Officer | Sell | −18,629 | −$644.83K |
| 2026-01-05 | Sravan Kumar Emany | Chief Financial Officer | Sell | −6,294 | −$170.57K |
| 2026-01-05 | Amy Simon | Chief Medical Officer | A | +12,500 | — |
| 2026-01-05 | Christine Bellon | Chief Legal Officer | Sell | −1,254 | −$33.98K |
| 2025-10-29 | FMR LLC | 10%+ Owner | Sell | −459 | −$12.25K |
| 2025-10-08 | FMR LLC | 10%+ Owner | G | −1,232,434 | — |
| 2025-10-03 | Christine Bellon | Chief Legal Officer | Sell | −373 | −$9.15K |
| 2025-10-03 | Bethany J Cavanagh | SVP, Finance and Treasurer | Sell | −467 | −$11.46K |
| 2025-10-03 | John M. Evans | CEO | MIXED | — | −$1.19M |
| 2025-08-01 | FMR LLC | 10%+ Owner | Sell | −48,374 | −$991.67K |
| 2025-07-03 | Amy Simon | Chief Medical Officer | Sell | −1,250 | −$23.96K |
| 2025-06-06 | John Maraganore | Director | A | +33,662 deriv. | — |
| 2025-06-06 | Mark Fishman | Director | A | +33,662 deriv. | — |
| 2025-06-06 | Carole Ho | Director | A | +33,662 deriv. | — |
| 2025-06-06 | Graham K Cooper | Director | A | +33,662 deriv. | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| John M. Evans | CEO | 1,175,205 | $29.26M |
| FMR LLC | 10%+ Owner | 1,106,071 | $27.54M |
| Giuseppe Ciaramella | President | 253,911 | $6.32M |
| Christine Bellon | Chief Legal Officer | 109,711 | $2.73M |
| Sravan Kumar Emany | Chief Financial Officer | 105,456 | $2.63M |
| Amy Simon | Chief Medical Officer | 85,696 | $2.13M |
| Bethany J Cavanagh | SVP, Finance and Treasurer | 50,984 | $1.27M |
| Mark Fishman | Director | 17,007 | $423.47K |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the BEAM quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.